Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial-Reference-Cited by-同舟云学术

Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial

Published:2022-03 Issue:3 Volume:23 Page:353-361
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Yan Min,Ouyang Quchang,Sun Tao,Niu Limin,Yang Jin,Li Li,Song Yuhua,Hao Chunfang,Chen Zhanhong,Orlandi Armando,Ishii Naohiro,Takabe Kazuaki,Franceschini Gianluca,Ricci Francesco,Verschraegen Claire,Liu Zhenzhen,Zhang Mengwei,Lv Huimin,Liu Liping,Yang Xiaohong,Xiao Huawu,Gao Zhichao,Li Xiaorui,Dong Fangyuan,Chen Xiuchun,Qiao Jianghua,Zhang Guifang

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma;Bendell;Cancer,2003

2. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors;Gori;Oncologist,2007

3. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER;Brufsky;Clin Cancer Res,2011

4. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era;Olson;Breast,2013

5. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study;Kocher;J Clin Oncol,2011

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy;European Journal of Medicinal Chemistry;2024-10

2. Efficacy and safety of pyrotinib-based regimens in HER2 positive metastatic breast cancer: A retrospective real-world data study;Neoplasia;2024-10

3. Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study;Clinical Breast Cancer;2024-08

4. Treatment of HER2-Positive Breast Cancer with Brain Metastases Using Anlotinib and Trastuzumab Deruxtecan: A Case Report;International Journal of Women's Health;2024-07

5. Exploring the feasibility and implications of cranioencephalic computed tomography in HER2-positive breast cancer: A pilot study;Heliyon;2024-07